Curis, Inc. (NASDAQ:CRIS) Shares Shorted: Short Interest Up 144.8% in October

Posted by Brian Himes on Oct 31st, 2026

Curis, Inc. (NASDAQ:CRIS – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 439,270 shares, a growth of 144.8% from the September 30th total of 179,462 shares. Based on an average daily trading volume, of 224,716 shares, the short-interest ratio is presently 2.0 days. Approximately 22.3% of the shares of the company are sold short.

Curis Stock Performance

CRIS traded up $0.05 during trading on Friday, hitting $0.60. The stock had a trading volume of 913,194 shares, compared to its average volume of 591,004. The firm has a market capitalization of $1.25 million, a P/E ratio of -0.04 and a beta of 3.11. The company’s 50-day moving average price is $0.92 and its 200 day moving average price is $9.10. Curis has a twelve month low of $0.33 and a twelve month high of $31.80.

Curis (NASDAQ:CRIS – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, topping analysts’ consensus estimates of ($6.95) by $2.93. As a group, equities analysts expect that Curis will post -15.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRIS has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of Curis in a research note on Monday, August 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research report on Thursday, October 15th. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Zacks Research raised Curis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $43.00.

Check Out Our Latest Stock Report on Curis

Institutional Investors Weigh In On Curis

Hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC acquired a new position in Curis during the 2nd quarter worth approximately $1,033,171,000. Stonepine Capital Management LLC acquired a new stake in shares of Curis in the 2nd quarter valued at approximately $1,729,292,000. Cable Car Capital LP acquired a new stake in shares of Curis in the 2nd quarter valued at approximately $696,000. Flputnam Investment Management Co. acquired a new stake in shares of Curis in the 2nd quarter valued at approximately $128,000. Finally, BlackRock Inc. purchased a new stake in shares of Curis in the second quarter valued at approximately $28,000. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

(Get Free Report)

Curis, Inc is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation.

Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.